Status:
COMPLETED
Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases
Lead Sponsor:
University of Milano Bicocca
Conditions:
Thalassemia Major
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
In Italy there are about 5000 patients with dependent transfusion thalassemia (source Italian Thalassemia and Hemoglobinopathies - SITE) and a smaller number, currently not definable, of patients with...
Detailed Description
INTRODUCTION In Italy there are about 5000 patients with dependent transfusion thalassemia (source Italian Thalassemia and Hemoglobinopathies - SITE) and a smaller number, currently not definable, of ...
Eligibility Criteria
Inclusion
- Patients with inherited dependent transfusion anemias (thalassemia major and intermediate, sickle cell anemia and Blackfan-Diamond anemia) or undergoing recurrent transfusion procedures (erythro-exchange in sickle cell anemia), belonging to the Rare Disease Center - ASST-Monza, Hospital S Gerardo.
- Age greater than or equal to 18 years.
Exclusion
- No exclusion criteria are expected apart from patients' refusal to participate in the study.
Key Trial Info
Start Date :
July 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 3 2020
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04526405
Start Date
July 14 2020
End Date
November 3 2020
Last Update
November 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST Monza - Ospedale San Gerardo
Monza, MB, Italy, 20900